Weight-loss drugs developer Kailera surges 62.5% in Nasdaq debut
17/04/2026 18:27
April 17 (Reuters) - Kailera Therapeutics' KLRA.O shares rose 62.5% in their Nasdaq debut on Friday after the weight-loss drug developer raised $625 million in its U.S. initial public offering. (Reporting by Manya Saini in Bengaluru; Editing by Sahal Muhammed) ((Manya.Saini@thomsonreuters.com; X: manya__saini;))
Recent news on Kailera Therapeutics
See all newsKardigan surges in Nasdaq debut after upsized $400 million IPO (updated)
Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
Advisory: Research alert on Kailera Therapeutics withdrawn
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut (updated)
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut